Drugs / PILAVAPADIN
PILAVAPADIN
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06203002 | Nov 2023 → Jan 2025 | diabetic polyneuropathy | Lexicon Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT04662281 | Dec 2020 → Nov 2022 | postherpetic neuralgia | Lexicon Pharmaceuticals | Completed | Missed primary |
| Phase 2 | NCT04455633 | Sep 2020 → May 2022 | diabetes mellitus, diabetic polyneuropathy | Lexicon Pharmaceuticals | Completed | Met primary |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PILAVAPADIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL5089410 ↗ |
| Known as | AAK1-IN-1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5089410 ↗ |
| Known as | BMS-986176 | “BMS-986176/LX-9211 (34) was identified as a highly selective, CNS penetrant, potent AAK1 inhibitor from a novel class of bi(hetero)aryl ethers.” PMID 35257579 ↗ Mar 2022 |
| Known as | LX-9211 | “BMS-986176/LX-9211 (34) was identified as a highly selective, CNS penetrant, potent AAK1 inhibitor from a novel class of bi(hetero)aryl ethers.” PMID 35257579 ↗ Mar 2022 |
| Known as | Pilavapadina | ChEMBL registry synonym — accepted as the source's own label CHEMBL5089410 ↗ |
| Known as | Pilavapadine | ChEMBL registry synonym — accepted as the source's own label CHEMBL5089410 ↗ |
| Action | Inhibit | “BMS-986176/LX-9211 (34) was identified as a highly selective, CNS penetrant, potent AAK1 inhibitor” PMID 35257579 ↗ Mar 2022 |
| Modality | Small molecule | — CHEMBL5089410 ↗ |
| Route | Oral | “participants were randomized to receive a single loading dose of LX9211, 100 milligrams (mg), tablet, orally, on Day 1” NCT04455633 ↗ |